Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency [Phase 1]

View source ↗

Summary

A Phase 1 trial to evaluate the safety and efficacy of CSB-001 Ophthalmic Solution 0.1% for limbal stem cell deficiency is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limbal Stem Cell Deficiency

Drugs mentioned

• CSB-001 Ophthalmic Solution 0.1% (CSB-001)

Snippet

Sponsor: Claris Biotherapeutics, Inc. | Conditions: Limbal Stem Cell Deficiency | Phase 1 | Status: RECRUITING